Detalhe da pesquisa
1.
Relapse patterns in early-PET negative, limited-stage Hodgkin lymphoma (HL) after ABVD with or without radiotherapy-a joint analysis of EORTC/LYSA/FIL H10 and NCRI RAPID trials.
Br J Haematol
; 200(6): 731-739, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541117
2.
Immunotherapy with CD25/CD71-allodepleted T cells to improve T-cell reconstitution after matched unrelated donor hematopoietic stem cell transplant: a randomized trial.
Cytotherapy
; 25(1): 82-93, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36220712
3.
Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.
Haematologica
; 107(9): 2051-2063, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34788984
4.
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.
Lancet Oncol
; 22(3): 332-340, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33539729
5.
FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
Br J Haematol
; 192(3): 504-513, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32621535
6.
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Br J Haematol
; 193(4): 750-760, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33650100
7.
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
Br J Haematol
; 192(6): 1015-1019, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32436212
8.
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
Br J Haematol
; 190(4): 545-554, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32150649
9.
Treatment of classical Hodgkin lymphoma in young adults aged 18-30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012).
Br J Haematol
; 189(1): 128-132, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31710702
10.
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Blood
; 132(20): 2154-2165, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181174
11.
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.
Br J Haematol
; 184(6): 999-1005, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30560573
12.
Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including 18F-FDG-PET-CT.
Eur Radiol
; 29(1): 202-212, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29948084
13.
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.
Lancet Oncol
; 19(10): 1328-1337, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30220622
14.
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Br J Haematol
; 196(4): e33-e37, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636043
15.
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
Br J Haematol
; 192(1): e14-e16, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222153
16.
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
Br J Haematol
; 193(3): e19-e22, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33715154
17.
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Br J Haematol
; 185(5): 948-951, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30460696
18.
Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrom macroglobulinaemia.
Leukemia
; 38(4): 822-828, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38409530
19.
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
Lancet Haematol
; 10(2): e93-e106, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36529145
20.
Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia.
Blood Adv
; 7(15): 3862-3873, 2023 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36867579